Synthesis, characterization and docking studies of novel series of benzothiazoles for anticancer activity

Cancer is the main cause of mortality worldwide, accounting for the majority of deaths. There is a therapeutic need for innovative, selective anti-tumor medicines that avoid most of the undesirable negative reactions linked to current chemotherapy regimens. The receptor for epidermal growth factor (EGFR) is a membrane glycoprotein, and mutations that cause EGFR overexpression or overactivity have been linked to a range of human malignancies.

In light of this, benzothiazole compounds were developed and produced as EGFR inhibitors, which could possibly form a new class of successful cancer therapies.

In this study, we synthesized novel [4-(1H-benzothiazol-2-yl) phenyl] amides derivatives. Furthermore, these produced compounds were subjected to molecular docking experiments to elaborate on interaction and chemistry in order to determine their affinity for the target. After confirming their molecular makeup, these compounds were tested for anticancer efficacy.

Benzothiazole molecules were effectively synthesized, and their molecular structures were verified using protons NMR and IR spectra. The cytotoxic activity of these novel compounds was determined using the SRB technique.

The present investigation involves the targeted chemotherapy to plausibly reverse, suppress or prevent cancer. Synthesized compounds revealed good cytotoxic effect and have shown more potential. So, in future, these effective molecules will be explored for increasing their affinity towards different targets, so they can be used against various cancers.